Concerning this, EGCG pre-treatment at the dose of 10 μM in SH-SY5Y cells, human-derived neuroblastoma cell line as a cell model of neurodegenerative disease, significantly increased the TfR to 185 ± 20% of control and 5 μM of EGCG induced TfR mRNA expressions to 336 ± 33% of control, indicating a reduced in the intracellular iron pool due to the chelating activity of EGCG [141]. This evidence concerns the gene TFRC and neurodegenerative disease.